Across TCGA pan-cancer cohorts, OR6K3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR6K3 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR6K3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR6K3 expression acts as an unfavorable survival marker.
OV, HNSC, and COAD are the cancer types where OR6K3 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.